A review study of targeting of AAK1 and JAK1/2 using baricitinib in COVID-19 infected human cells
The outbreak of a current public health coronavirus 2019 disease is a causative agent of a serious acute respiratory syndrome and even death. COVID-19 has exposed to multi-suggested pharmaceutical agents to control this global disease. Baricitinib, a well-known antirheumatic agent, was one of...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Baghdad/ Al-Kindy College of Medicine
2020-07-01
|
| Series: | مجله كليه طب الكندي |
| Subjects: | |
| Online Access: | https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/176 |
| _version_ | 1818480622480392192 |
|---|---|
| author | Abeer M Al-Humaidhi |
| author_facet | Abeer M Al-Humaidhi |
| author_sort | Abeer M Al-Humaidhi |
| collection | DOAJ |
| description |
The outbreak of a current public health coronavirus 2019 disease is a causative agent of a serious acute respiratory syndrome and even death. COVID-19 has exposed to multi-suggested pharmaceutical agents to control this global disease. Baricitinib, a well-known antirheumatic agent, was one of them. This article reviews the likely pros and cons of baricitinib in attenuation of COVID-19 based on the mechanism of drug action as well as its pharmacokinetics. The inhibitory effect of baricitinib on receptor mediated endocytosis promoter, AKK1, and on JAK-STAT signaling pathway is benefacial in inhibition of both viral assembling and inflammation. Also, its pharmacokinetic has encouraged the physicians toward the drug selection for COVID-19 treatment. On the other hand, most of baricitinib side effects are dose-dependent. In conclusion, targeting of AAK1 and JAK1/2 using baricitinib has predicted to be potential and effective with minimal side effects in management COVID-19 infected patients for a short therapeutic dosing period. Laboratory monitoring should be considered for some parameters. However, experimental trials are mandatory for a long-term treatment with a lower dose of baricitinib to evaluate its effectiveness and safety in patients with moderate COVID-19 infection.
|
| first_indexed | 2024-12-10T11:25:36Z |
| format | Article |
| id | doaj.art-663c2b04098b4f4f81c99e702b8c5603 |
| institution | Directory Open Access Journal |
| issn | 1810-9543 2521-4365 |
| language | English |
| last_indexed | 2024-12-10T11:25:36Z |
| publishDate | 2020-07-01 |
| publisher | University of Baghdad/ Al-Kindy College of Medicine |
| record_format | Article |
| series | مجله كليه طب الكندي |
| spelling | doaj.art-663c2b04098b4f4f81c99e702b8c56032022-12-22T01:50:45ZengUniversity of Baghdad/ Al-Kindy College of Medicineمجله كليه طب الكندي1810-95432521-43652020-07-0116supplement10.47723/kcmj.v16isupplement.176A review study of targeting of AAK1 and JAK1/2 using baricitinib in COVID-19 infected human cellsAbeer M Al-Humaidhi The outbreak of a current public health coronavirus 2019 disease is a causative agent of a serious acute respiratory syndrome and even death. COVID-19 has exposed to multi-suggested pharmaceutical agents to control this global disease. Baricitinib, a well-known antirheumatic agent, was one of them. This article reviews the likely pros and cons of baricitinib in attenuation of COVID-19 based on the mechanism of drug action as well as its pharmacokinetics. The inhibitory effect of baricitinib on receptor mediated endocytosis promoter, AKK1, and on JAK-STAT signaling pathway is benefacial in inhibition of both viral assembling and inflammation. Also, its pharmacokinetic has encouraged the physicians toward the drug selection for COVID-19 treatment. On the other hand, most of baricitinib side effects are dose-dependent. In conclusion, targeting of AAK1 and JAK1/2 using baricitinib has predicted to be potential and effective with minimal side effects in management COVID-19 infected patients for a short therapeutic dosing period. Laboratory monitoring should be considered for some parameters. However, experimental trials are mandatory for a long-term treatment with a lower dose of baricitinib to evaluate its effectiveness and safety in patients with moderate COVID-19 infection. https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/176Adaptor-associated protein kinase-1; baricitinib; COVID-19; cytokines; Janus Kinases. |
| spellingShingle | Abeer M Al-Humaidhi A review study of targeting of AAK1 and JAK1/2 using baricitinib in COVID-19 infected human cells مجله كليه طب الكندي Adaptor-associated protein kinase-1; baricitinib; COVID-19; cytokines; Janus Kinases. |
| title | A review study of targeting of AAK1 and JAK1/2 using baricitinib in COVID-19 infected human cells |
| title_full | A review study of targeting of AAK1 and JAK1/2 using baricitinib in COVID-19 infected human cells |
| title_fullStr | A review study of targeting of AAK1 and JAK1/2 using baricitinib in COVID-19 infected human cells |
| title_full_unstemmed | A review study of targeting of AAK1 and JAK1/2 using baricitinib in COVID-19 infected human cells |
| title_short | A review study of targeting of AAK1 and JAK1/2 using baricitinib in COVID-19 infected human cells |
| title_sort | review study of targeting of aak1 and jak1 2 using baricitinib in covid 19 infected human cells |
| topic | Adaptor-associated protein kinase-1; baricitinib; COVID-19; cytokines; Janus Kinases. |
| url | https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/176 |
| work_keys_str_mv | AT abeermalhumaidhi areviewstudyoftargetingofaak1andjak12usingbaricitinibincovid19infectedhumancells AT abeermalhumaidhi reviewstudyoftargetingofaak1andjak12usingbaricitinibincovid19infectedhumancells |